Castration resistant prostate cancer, beyond the usual treatment

Location: Room 14b (ICM, Level 1)

Chairs: T.A. Borkowski, Warsaw (PL)
S. Egawa, Tokyo (JP)
A. Necchi, Milan (IT)

Aims and objectives of this presentation
The treatment Castration Resistant Prostate Cancer has been revolutionised over the years. Understanding its complexity is a major challenge for most urologists. This session will help understand the latest developments in the area.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*764

Radium-223 (Ra-223) re-treatment (re-tx): Experience from an international, multicenter, prospective study in patients (pts) with castration-resistant prostate cancer and bone metastases (mCRPC)
Institutes: Meir Medical Center, Dept. of Genitourinary Oncology Service, Kfar-Saba, Israel, 2GU Research Network, LLC, Dept. of Medical Oncology, Omaha, Nebraska, United States of America, 3Associated Medical Professionals of New York, PLLC, Dept. of Radiation Oncology, Syracuse, New York, United States of America, 4Hospital Universitario Reina Sofia, Dept. of Medical Oncology, Cordoba, Spain, 5Cancer Center Norrland University, Dept. of Radiation Sciences, Umeå, Sweden, 6Rambam Medical Center, Dept. of Oncology, Haifa, Israel, 7Foundation IRCCS National Cancer Institute, Dept. of Medical Oncology, Milan, Italy, 8Hadassah Hebrew University Medical Center, Dept. of Oncology, Jerusalem, Israel, 9 Kuopio University Hospital, Dept. of Oncology, Kuopio, Finland, 10Romagnolo Scientific Institute For The Study and Care of Cancer - IRST IRCCS, Dept. of Nuclear Medicine Therapeutic, Meldola, Italy, 11Hospital Universitario Virgen De La Victoria, Dept. of Medical Oncology, Malaga, Spain, 12Bayer HealthCare, Dept. of Global Clinical Development, Whippany, New Jersey, United States of America, 13Bayer HealthCare, Dept. of Global Research & Development Statistics, Whippany, New Jersey, United States of America, 14Tulane Cancer Center, Dept. of Medicine and Urology, New Orleans, Louisiana, United States of America

*765

Updated long-term efficacy and safety of androgen receptor inhibitor ODM-201 in phase I/II trial
By: Fizazi K.1, Massard C.1, Bono P.2, Kataja V.3, James N.4, Tammela T.5, Joensuu H.2, Aspegren J.6, Mustonen M.V.6
Institutes: 1Institut Gustave Roussy, Dept. of Cancer Medicine, Villejuif, France, 2Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki, Finland, 3Kuopio University Hospital, Jyväskylä Central Hospital, Kuopio, Finland, 4Queen Elizabeth Hospital University Hospitals, Birmingham NHS Foundation Trust, Birmingham, Finland, 5Tampere University Hospital, Dept. of Urology, Tampere, Finland, 6Orion Corporation Orion Pharma, Research and Development, Espoo, Finland

*766

Statin use and prostate cancer mortality
By: Benzon Larsen S.1, Skriver C.1, Dehle Jordfoss C.1, Jespersen C.2, Borre M.3, Nørgård M.4, Brasso K.5, Andersen K.K.1, Sørensen H.4, Hallas J.6, Friis S.1
Institutes: 1Danish Cancer Society, Research Centre, Copenhagen, Denmark, 2Viborg Hospital, Dept. of Urology, Viborg, Denmark, 3Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, 4...
Testosterone bounce predicts cancer specific survival of prostate cancer patients treated with docetaxel therapy
By: Shuhei K.1, Sakamoto S.2, Yamamoto S.1, Inoue T.1, Nozumi K.1, Chiba K.1, Miyazaki K.1, Atsushi I.1, Nagata M.1
Institutes: Yokohama Rosai Hospital, Dept. of Urology, Yokohama City, Kanagawa, Japan, Chiba Univ. Hospital, Dept. of Urology, Chiba, Japan

Effect of PSA response on overall and progression-free survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel (Caba): The non-interventional study QoLiTime
By: Hammerer P.1, Al-Batran S-E.2, Windemuth-Kieselbach C.3, Hofheinz R.-D.4
Institutes: Academic Hospital Braunschweig, Dept. of Urology and Uro-Oncology, Braunschweig, Germany, Nordwest Hospital, Institute of Clinical Research, Frankfurt, Germany, Alcedis GmbH, Dept. of Biometry, Gießen, Germany, University Hospital Mannheim, Interdisciplinary Tumor Center, Mannheim, Germany

Initial clinical experience with 177Lu-PSMA I&T radionuclide therapy in patients with metastatic castration-resistant prostate cancer
By: Heck M.M.1, Retz M.1, Rauscher I.2, Scheidhauer K.2, Maurer T.1, Storz E.1, Janssen F.1, D’Alessandria C.1, Wester H.-J.3, Gschwend J.E.3, Schwaiger M.2, Tauber R.1, Eiber M.2
Institutes: Klinikum Rechts der Isar der Technischen Universität München, Dept. of Urology, Munich, Germany, Klinikum Rechts der Isar der Technischen Universität München, Dept. of Nuclear Medicine, Munich, Germany, Technische Universität München, Dept. of Pharmaceutical Radiochemistry, Garching, Germany

Hormonal response after long-term androgen suppression in patients with prostate cancer
By: Planas Morin J.1, Celma A.1, Regis L.1, Cuadras M.1, Trilla E.1, Salvador C.1, Placer J.1, Lorente D.1, Carles J.2, Suárez C.2, Morote J.1
Institutes: Hospital Universitari Vall d’Hebron, Dept. of Urology, Barcelona, Spain, Hospital Universitari Vall d’Hebron, Dept. of Oncology, Barcelona, Spain

Real-world treatment patterns and factors influencing the use of bone-targeted agents (BTAs) in combination with emerging therapeutics in patients with prostate cancer and bone-metastases
By: Body J-J.1, Von Moos R.2, Rider A.3, Bhowmik D.4, Hallworth P.1, Hechmati G.5, Qian Y.4, Gatta F.5
Institutes: Chu Brugmann, Dept. Of Medicine, Brussels, Belgium, Kantonsspital Graubünden, Dept. of Oncology, Chur, Switzerland, Adelphi Real World, Bollington, United Kingdom, Amgen Inc., Dept. of Health Economics, Thousand Oaks, United States of America, Amgen (Europe) GmbH, Dept. of Health Economics, Zug, Switzerland

Which factors predict overall survival in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate post-docetaxel?
Institutes: Ghent University Hospital, Dept. of Urology, Ghent, Belgium, Ghent University Hospital, Dept. of Medical Oncology, Ghent, Belgium, Leuven University Hospital, Dept. of Medical Oncology, Leuven, Belgium, AZ Turnhout, Dept. of Medical Oncology, Turnhout, Belgium, AZ Klinia, Dept. of Medical Oncology, Brasschaat, Belgium, AZ Delta, Dept. of Medical Oncology, Roeselare, Belgium, AZ Imelda, Dept. of Medical Oncology, Bonheiden, Belgium, Institut Jules Bordet, Dept. of Medical Oncology, Brussels, Belgium, OLV Aalst, Dept. of Urology, Aalst, Belgium, Hospital De Jolimont, Dept. of Medical Oncology, Haine Saint Paul, Belgium, Brussels University Hospital, Dept. of Medical Oncology, Brussels, Belgium, Cliniques Universitaires Saint Luc, Dept. of
*773 Abiraterone for castration resistant prostate cancer: Adherence, survival and hospitalization: Analysis of a medical claims database
By: Mohamad Al-Ali B.1, Madersbacher S.1, Berger I.2
Institutes: 1Kaiser-Franz-Josef Spital, Dept. of Urology and Andrology, Vienna, Austria, 2Klinikum Wiener Neustadt, Dept. of Urology and Andrology, Wiener Neustadt, Austria

*774 ARV7 detected by a novel whole-blood RT-PCR assay correlates with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI)
By: Todenhöfer T.1, Azad A.2, Gao J.1, Stewart C.1, Eigl B.2, Stenzl A.4, Black P.1, Teich M.3, Joshua A.3, Chi K.2
Institutes: 1University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada, 2British Columbia Cancer Agency, Dept. of Medical Oncology, Vancouver, Canada, 3University of Toronto, Princess Margaret Cancer Centre, Toronto, Canada, 4Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany

*775 The phase 3 COU-AA-302 study of abiraterone acetate (AA) in men with chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC): Stratified analysis based on pain, prostate-specific antigen (PSA) and Gleason score (GS)
By: Miller K.1, Carles J.2, Gschwend J.E.3, Van Poppel H.4, Diels J.5, Brookman-May S.D.6
Institutes: 1Charité Berlin, Dept. of Urology, Berlin, Germany, 2Vall D’Hebron University Hospital, Dept. of Medical Oncology, Barcelona, Spain, 3Technical University of Munich, School of Medicine, Munich, Germany, 4Katholieke Universiteit Leuven, Dept. of Urology, Leuven, Belgium, 5Janssen EMEA, HEMAR, Beerse, Belgium, 6Ludwig Maximilians University of Munich, Janssen Research & Development, Munich, Germany